Brain immunology and immunotherapy in brain tumours.
Publication
, Journal Article
Sampson, JH; Gunn, MD; Fecci, PE; Ashley, DM
Published in: Nat Rev Cancer
January 2020
Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet, seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of the immune system within the central nervous system (CNS) and altered the paradigm for successful immunotherapy. The impact of standard therapies on the response to immunotherapy is now better understood, as well. This new knowledge has implications for a broad range of tumours that develop within the CNS. Nevertheless, the requirements for successful therapy remain effective delivery and target specificity, while the dramatic heterogeneity of malignant gliomas at the genetic and immunological levels remains a profound challenge.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Rev Cancer
DOI
EISSN
1474-1768
Publication Date
January 2020
Volume
20
Issue
1
Start / End Page
12 / 25
Location
England
Related Subject Headings
- Tumor Microenvironment
- Treatment Outcome
- Standard of Care
- Oncology & Carcinogenesis
- Immunotherapy
- Immunomodulation
- Immunity
- Humans
- Disease Susceptibility
- Disease Management
Citation
APA
Chicago
ICMJE
MLA
NLM
Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2020). Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer, 20(1), 12–25. https://doi.org/10.1038/s41568-019-0224-7
Published In
Nat Rev Cancer
DOI
EISSN
1474-1768
Publication Date
January 2020
Volume
20
Issue
1
Start / End Page
12 / 25
Location
England
Related Subject Headings
- Tumor Microenvironment
- Treatment Outcome
- Standard of Care
- Oncology & Carcinogenesis
- Immunotherapy
- Immunomodulation
- Immunity
- Humans
- Disease Susceptibility
- Disease Management